Adverum Biotechnologies Inc (ADVM)
10.43
+0.43
(+4.30%)
USD |
NASDAQ |
May 03, 16:00
10.47
+0.04
(+0.38%)
After-Hours: 20:00
Adverum Biotechnologies Cash and Short Term Investments (Quarterly): 96.53M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 96.53M |
| September 30, 2023 | 117.08M |
| June 30, 2023 | 141.45M |
| March 31, 2023 | 164.28M |
| December 31, 2022 | 185.59M |
| September 30, 2022 | 203.26M |
| June 30, 2022 | 235.84M |
| March 31, 2022 | 271.06M |
| December 31, 2021 | 305.19M |
| September 30, 2021 | 332.70M |
| June 30, 2021 | 363.84M |
| March 31, 2021 | 404.02M |
| December 31, 2020 | 429.73M |
| September 30, 2020 | 454.46M |
| June 30, 2020 | 280.14M |
| March 31, 2020 | 297.07M |
| December 31, 2019 | 166.04M |
| September 30, 2019 | 161.98M |
| June 30, 2019 | 177.64M |
| March 31, 2019 | 189.49M |
| December 31, 2018 | 205.08M |
| Date | Value |
|---|---|
| September 30, 2018 | 217.88M |
| June 30, 2018 | 234.88M |
| March 31, 2018 | 247.04M |
| December 31, 2017 | 190.48M |
| September 30, 2017 | 186.64M |
| June 30, 2017 | 197.42M |
| March 31, 2017 | 209.50M |
| December 31, 2016 | 222.17M |
| September 30, 2016 | 231.27M |
| June 30, 2016 | 241.30M |
| March 31, 2016 | 247.08M |
| December 31, 2015 | 259.08M |
| September 30, 2015 | 268.89M |
| June 30, 2015 | 279.64M |
| March 31, 2015 | 290.12M |
| December 31, 2014 | 159.40M |
| September 30, 2014 | 165.33M |
| June 30, 2014 | 52.43M |
| March 31, 2014 | 50.68M |
| December 31, 2013 | 0.564M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
96.53M
Minimum
Dec 2023
454.46M
Maximum
Sep 2020
252.00M
Average
235.84M
Median
Jun 2022
Cash and Short Term Investments (Quarterly) Benchmarks
| Karyopharm Therapeutics Inc | 191.44M |
| Ardelyx Inc | 184.30M |
| Minerva Neurosciences Inc | 40.91M |
| Arcutis Biotherapeutics Inc | 271.86M |
| 4D Molecular Therapeutics Inc | 288.23M |